Pricing & Access· May 26, 2026 · 7 min read
Veppanu (vepdegestrant) coverage guide: the first PROTAC degrader for ER+/HER2− breast cancer
By Ran Chen#PROTAC#Breast Cancer#Companion Diagnostic
Topic
Breast Cancer
Breast cancer drug access, ER+/HER2− targeting, biomarker-driven therapy, companion diagnostics, and oncology coverage workflows.